Replies to post #16308 on Cytogenix (fka CYGX)

[CD_98]

What I just posted will apply to any phase trials CYGX may go through. The FDA may be more forgiving in the case of preclinicals. Here's hoping they conform to cGMPs.

[HANUMAN]

CD, you have a short memory. Reread this press release. MS is not a bumbling know-nothing:
NASA Contractor Senior Scientist Joins CytoGenix
Houston, TX, (September 14, 2004) Cytogenix, Inc. (CYGX: OTC: BB)

CytoGenix, Inc. (CYGX: OTC: BB) announces that Kurt L. Berens has agreed to join the company as Vice President of Product Development. Formerly a Section Manager for Wyle Laboratories, Cellular and Biomedical Group at NASA-Johnson Space Center, Houston, Berens has over fifteen years of clinical research experience.

Dr. Malcolm Skolnick, CytoGenix CEO, states, "Kurt is an excellent clinical scientist with experience in drug development and successes in the FDA drug approval process. Because of the promise of our technology, CytoGenix continues to attract outstanding professionals. Our discovery programs will continue to yield a flow of new products to complement our two lead drug candidates. From these efforts, we plan to submit several IND applications in the upcoming months."

Prior to his work at NASA, Berens was Senior Project Manager for Clinical Development and Regulatory Affairs at Texas Biotechnology Corp. of Houston, Texas where he was responsible for managing successful clinical trials of the company's lead drug. He has authored or co-authored twenty scientific published papers and two book chapters. He has been an Instructor of Bio-pharmaceutics and Pharmacokinetics at University of Houston, College of Pharmacy and an Instructor of Pharmacotherapeutics in Space Medicine at the University of Texas Medical Branch Galveston.